Provectus Biopharmaceuticals (PVCT) Stock Chart & Stock Price History $0.11 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Chart Stock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Provectus Biopharmaceuticals Stock Price Performance 5 Day Performance+3.36%1 Month Performance+6.36%3 Month Performance+9.95%6 Month Performance-40.11%Year-To-Date Performance+18.54%1 Year Performance-20.97% Receive PVCT Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Provectus Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address My #1 Pre IPO Trade for 2025 – NAME and TICKER (Ad)One tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...The Next SpaceX Pre-IPO PVCT Stock Chart for Thursday, November, 21, 2024 PVCT Chart by TradingView Provectus Biopharmaceuticals Stock Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization11/20/2024$0.11$0.11+0.05%$0.11$0.11251,750 shs$46.27 million11/19/2024$0.11$0.11-1.74%$0.11$0.10205,979 shs$46.25 million11/18/2024$0.11$0.11+1.73%$0.11$0.10312,800 shs$47.07 million11/15/2024$0.11$0.11-0.81%$0.11$0.11837,440 shs$46.27 million11/14/2024$0.11$0.11-0.45%$0.11$0.11762,932 shs$46.65 million11/13/2024$0.11$0.11-1.68%$0.12$0.11452,914 shs$46.86 million Get the Latest News and Ratings for PVCT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Provectus Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 11/12/2024$0.11$0.11+5.88%$0.11$0.11517,506 shs$47.66 million11/11/2024$0.11$0.11-0.83%$0.11$0.1030,841 shs$45.01 million11/08/2024$0.11$0.11-1.82%$0.11$0.10346,235 shs$45.39 million11/07/2024$0.11$0.11-3.34%$0.11$0.106,013 shs$46.23 million11/06/2024$0.11$0.11+4.12%$0.11$0.1059,139 shs$47.83 million11/05/2024$0.11$0.11+1.30%$0.11$0.1140,605 shs$45.94 million11/04/2024$0.10$0.11+4.55%$0.11$0.1054,600 shs$45.35 million11/01/2024$0.11$0.10-4.00%$0.11$0.10153,474 shs$43.37 million10/31/2024$0.11$0.11+0.47%$0.11$0.10127,951 shs$45.18 million10/30/2024$0.11$0.11+0.66%$0.11$0.10253,161 shs$44.97 million10/29/2024$0.11$0.11-1.94%$0.11$0.10595,290 shs$44.68 million10/28/2024$0.11$0.11$0.11$0.1059,749 shs$45.56 million10/25/2024$0.11$0.11+0.84%$0.11$0.10103,971 shs$45.48 million10/24/2024$0.11$0.11-0.37%$0.11$0.1150,225 shs$45.18 million10/23/2024$0.11$0.11+0.84%$0.11$0.112,966 shs$45.35 million10/22/2024$0.11$0.11$0.11$0.1116,400 shs$44.97 million10/21/2024$0.11$0.11+0.09%$0.11$0.1176,823 shs$44.89 million Related Companies HRTX Stock Price Chart INZY Stock Price Chart TNYA Stock Price Chart NBTX Stock Price Chart CRBU Stock Price Chart KYTX Stock Price Chart SCPH Stock Price Chart NKTX Stock Price Chart GALT Stock Price Chart DMAC Stock Price Chart Receive PVCT Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Provectus Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. This page (OTCMKTS:PVCT) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Provectus Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Provectus Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
